The medicine has enjoyed a head-start over rivals but now faces competition from AstraZeneca's Fasenra. GSK will also present long-term data on Nucala - a new kind of biotech drug for severe asthma - at ATS. That leaves only a small contract team working on Advair. Miels, who was hired by new CEO Emma Walmsley last year from AstraZeneca, has redeployed resources to focus on such priority products and nearly all of GSK's more than 2,000 respiratory reps in the United States are now selling Trelegy and Nucala, plus two other relatively new lung drugs Breo and Anoro. "Time will tell but I hope that over time the analysts will move their numbers up." Outside the United States, which is likely to account for around 60 percent of sales, Trelegy has already launched in Britain and is now being rolled out in Germany and Canada.Ĭonsensus analyst forecasts compiled by Thomson Reuters don't predict it becoming a $1 billion-a-year blockbuster before 2023 but Miels said such estimates looked conservative. I think it's reasonable to think there will be some pressure with the introduction of Advair generics but we're confident we can manage that," he said. "We are not experiencing direct pressure on Trelegy at this point in time. Trelegy Ellipta is not a fast-acting rescue medicine to be used during an asthma attack. It combines an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA). GSK has priced Trelegy at a 20 percent discount to its components and the company has not reduced the price since its launch, but Miels acknowledged this might change once Advair generics arrive. Trelegy Ellipta is a once-daily therapy that combines three medicines into one inhaler. Since Trelegy includes all three products in a single inhaler, it is potentially caught in the cross-fire. Another class known as LAMA medicine is faring better. inhaler market is proving more severe than GSK had anticipated at the start of the year, particularly in the ICS/LABA area, which includes Advair.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |